Our data strongly suggest that FOXO4 suppresses metastatic invasiveness by preventing RUNX2 from activating a group of pro-metastatic genes including PIP, PGC, CAMK2N1 and PLA2G16. The finding that FOXO4 downregulation correlates with earlier onset metastatic disease in CaP patients strongly suggests that CaP metastasis could be antagonized by reactivating FOXO4 expression or by inhibiting RUNX2 function. This evidence concerns the gene RUNX2 and metastatic neoplasm.